Actively Recruiting
Study of Macrophage Activation Marker sCD163 to Predict Treatment Response to UDCA in Adults with Primary Biliary Cholangitis
Led by University of Aarhus · Updated on 2022-08-12
40
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Primary biliary cholangitis PBC is an autoimmune liver disease that causes damage to the small bile ducts inside the liver, leading to inflammation and possible progression to liver fibrosis and cirrhosis. Fatigue and itching are common symptoms that affect quality of life. This research aims to study the role of two markers, sCD163 and sMR, which are released by activated macrophages in the liver, to see if they can predict how well newly diagnosed PBC patients respond to the standard treatment with ursodeoxycholic acid UDCA. The study monitors patients newly diagnosed with PBC who have not yet started UDCA treatment. Researchers collect blood samples, perform Fibroscan imaging, and use questionnaires to assess disease progression over three years. Liver biopsies will only be reviewed if done as part of diagnosis, not solely for the study. The main focus is to determine if sCD163 and sMR levels measured before treatment can identify patients who might not respond well to UDCA and who may need additional therapies. Participants will be followed for at least one year to evaluate their response to UDCA based on blood test results, including liver enzyme levels and bilirubin. Further assessments such as blood tests, Fibroscan, and questionnaires will be done over three years to track disease progression. The study does not include treatment administration but observes patients receiving usual care while measuring these markers and clinical outcomes.
CONDITIONS
Brief Title
sCD163 in PBC Patients - Assessment of Treatment Response
Research Team
L
Lars Bossen, PhD-student
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here